Vanguard Group Inc. Sells 19,274 Shares of Bio-Rad Laboratories, Inc. $BIO

Vanguard Group Inc. trimmed its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 1.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,774,263 shares of the medical research company’s stock after selling 19,274 shares during the period. Vanguard Group Inc. owned about 0.07% of Bio-Rad Laboratories worth $537,584,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of BIO. Quent Capital LLC bought a new stake in Bio-Rad Laboratories in the 3rd quarter worth about $25,000. Farther Finance Advisors LLC increased its holdings in Bio-Rad Laboratories by 52.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after buying an additional 36 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after buying an additional 76 shares in the last quarter. CWM LLC increased its holdings in Bio-Rad Laboratories by 82.0% in the 3rd quarter. CWM LLC now owns 202 shares of the medical research company’s stock worth $57,000 after buying an additional 91 shares in the last quarter. Finally, UMB Bank n.a. boosted its position in Bio-Rad Laboratories by 24.0% in the third quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock worth $58,000 after purchasing an additional 40 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Trading Up 0.5%

Shares of NYSE:BIO opened at $257.80 on Tuesday. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $343.12. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21. The stock has a market capitalization of $6.96 billion, a price-to-earnings ratio of 42.47 and a beta of 1.06. The stock’s 50-day simple moving average is $277.81 and its two-hundred day simple moving average is $298.11.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 earnings per share for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The company had revenue of $592.10 million for the quarter, compared to analysts’ expectations of $589.91 million. During the same period in the previous year, the firm earned $2.54 earnings per share. The firm’s quarterly revenue was up 1.1% on a year-over-year basis. Analysts expect that Bio-Rad Laboratories, Inc. will post 10.32 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Wells Fargo & Company dropped their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research report on Friday. Citigroup cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $375.00 to $300.00 in a research report on Tuesday, April 7th. Finally, Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $333.00.

Get Our Latest Report on Bio-Rad Laboratories

About Bio-Rad Laboratories

(Free Report)

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.

Recommended Stories

• Five stocks we like better than Bio-Rad Laboratories

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).